Clinical Trials at NEXT Virginia
As of August 2026, 76 paid clinical trials are recruiting at NEXT Virginia, located at 12011 GOVERNMENT CENTER PKWY, SUITE 836, FAIRFAX, VA 22035-1100, phone (703) 324-7000 in Fairfax, Virginia. Active studies at this site cover conditions such as Advanced Solid Tumor, Ovarian Cancer and Endometrial Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Fairfax
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
78 clinical trials at NEXT Virginia
·Clear filters·Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
A Study of LY4175408 in Participants With Advanced Cancer
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
Study of XB010 in Subjects With Solid Tumors
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
A Study of PYX-201 in Advanced Solid Tumors
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
A Study of HLD-0117 in Patients With Metastatic Breast Cancer
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
Common conditions studied in Fairfax
- Advanced Solid Tumor (33 active studies)
- Ovarian Cancer (28 active studies)
- Endometrial Cancer (26 active studies)
- Advanced Solid Tumors (25 active studies)
- Breast Cancer (23 active studies)
- Colorectal Cancer (21 active studies)
Leading research sponsors in Fairfax
- AstraZeneca
- AbbVie
- Merck Sharp & Dohme LLC
- Eli Lilly and Company
- Janssen Research & Development, LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Fairfax?
There are approximately 492 recruiting clinical trials in Fairfax, Virginia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Fairfax pay participants?
Most recruiting trials in Fairfax compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Fairfax?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Fairfax?
The most common conditions under active study in Fairfax include Advanced Solid Tumor (33), Ovarian Cancer (28), Endometrial Cancer (26), Advanced Solid Tumors (25), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Fairfax?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Fairfax on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Fairfax?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Fairfax?
Recruiting research sites in Fairfax include NEXT Virginia, Virginia Cancer Specialists, Inova Schar Cancer Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Fairfax right now?
The largest active categories in Fairfax are Cancer & tumors (333), Cardiovascular (8), Neurology & pain (4). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of NEXT Virginia?
NEXT Virginia is located at 12011 GOVERNMENT CENTER PKWY, SUITE 836, FAIRFAX, VA 22035-1100. Use the Google Maps link in the intro above to get directions.
How do I contact NEXT Virginia?
You can reach NEXT Virginia by phone at (703) 324-7000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.